Nevertheless, no major clinical trials of PTGS2 inhibitors were completed in CRC due to their adverse effects, such as elevated risk of myocardial infarction, dyspepsia, abdominal pain, gastrointestinal bleeding, and gastritis19,54. Here, PTGS2 is linked to colorectal carcinoma.